Department of Biotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dong Ming Road, Jin-Shui District, Zhengzhou, Henan 450008, PR China.
Department of Biotherapy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dong Ming Road, Jin-Shui District, Zhengzhou, Henan 450008, PR China.
Int Immunopharmacol. 2018 Mar;56:143-147. doi: 10.1016/j.intimp.2018.01.019. Epub 2018 Feb 3.
This retrospective study aimed to investigate the prognostic value of pre-treatment platelet-to-lymphocyte ratio (PLR), which is an inflammatory indicator, in patients with melanoma.
Patients in this retrospective analysis were admitted between January 1, 2010 and December 31, 2015 in Henan Cancer Hospital. Receiver operating characteristic (ROC) curve was performed the optimal cut-off value for PLR. The 140 patients were divided into two groups: high PLR group and low PLR group. The relationship between PLR and overall survival (OS) was analyzed. The Kaplan-Meier and Log rank tests were used for univariate survival analysis and Cox proportional hazards regression model for multivariate analysis.
The optimal cut-off value of PLR determined by ROC curve was 120.15. Univariate and Cox multivariate survival analysis all showed that PLR and clinical stage were factors affecting OS in melanoma patients (P < 0.05). The overall median OS was 21.0 months (95% confidence interval (CI): 18.1-23.9), for 17.0 months in the high PLR group, and 34.0 months in the low PLR group (hazard ratio: 0.436, 95% CI: 0.291-0.652, P < 0.001), respectively. Clinical subgroup analysis showed that PLR was a risk factor in patients with stage II, III, and IV disease (P < 0.05).
The elevated PLR was an independent prognostic predictor for OS in patients with melanoma.
本回顾性研究旨在探讨血小板与淋巴细胞比值（PLR）这一炎症指标在黑色素瘤患者中的预后价值。
本回顾性分析纳入 2010 年 1 月 1 日至 2015 年 12 月 31 日期间在河南省肿瘤医院就诊的患者。通过受试者工作特征（ROC）曲线确定 PLR 的最佳截断值。将 140 例患者分为高 PLR 组和低 PLR 组。分析 PLR 与总生存期（OS）的关系。采用 Kaplan-Meier 法和 Log rank 检验进行单因素生存分析，Cox 比例风险回归模型进行多因素分析。
ROC 曲线确定的 PLR 最佳截断值为 120.15。单因素和 Cox 多因素生存分析均表明，PLR 和临床分期是影响黑色素瘤患者 OS 的因素（P<0.05）。总中位 OS 为 21.0 个月（95%置信区间：18.1-23.9），高 PLR 组为 17.0 个月，低 PLR 组为 34.0 个月（风险比：0.436，95%置信区间：0.291-0.652，P<0.001）。临床亚组分析显示，PLR 是 II 期、III 期和 IV 期患者的危险因素（P<0.05）。
升高的 PLR 是黑色素瘤患者 OS 的独立预后预测因素。
